Phase 3 N=339 A Study to Assess the Long-term Safety of QVA149
Chronic Obstructive Pulmonary Disease
Primary: Number of Participants With Adverse Events, Serious Adverse Events or Death — 130; 64; 37; 12 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=127 Trospium Chloride XR in Obese Female Patients With Overactive Bladder
Obesity · Overactive Bladder · Incontinence
Primary: Percent Change From Baseline in Urinary Urgency Incontinence (UUI) — -23.7; 57.8 Percent change
Phase 4 N=70 Knee Arthroplasty Performed With Conventional and Customized Instrumentation
Knee Arthritis
Primary: Length of Surgery — 3447.19; 3707.19 seconds
Phase 4 N=23 Does Omeprazole Decrease Intestinal Calcium Absorption?
Osteoporosis · Achlorhydria · GERD
Primary: Change in Intestinal Calcium Absorption From Baseline to One Month — 5 percent calcium absorption
N/A N=314 Rollover Protocol for Prior SU011248 Protocols
Solid Tumors
Primary: Duration of Treatment — 190 Days
Phase 1 N=31 Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia
Schizophrenia
Primary: Change From Baseline in Systolic Blood Pressure at Day 5: 50 mg — -0.14; 8.94 mmHg
Phase 4 N=18 Effect of Weight and/or Obesity on Caspofungin Drug Concentrations
Obesity · Fungal Infection
Primary: Total Clearance of Caspofungin — 0.508 L/hr
Phase 3 N=109 SANTE - Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy
Epilepsy
Primary: Primary Analysis: Change in Seizure Rate — -40.4; -14.5 Percentage change from baseline — p=0.0017
Phase 2 N=37 Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout
Gout
Primary: Reduction in Plasma Uric Acid to Less Than 6 mg/dL. — 17 Participants
Phase 2 N=214 Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region
Malaria
Primary: Number of Subjects With Serious Adverse Events (SAEs). — 17; 17 subjects
Phase 2 N=125 Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas
Glioblastoma · Gliosarcoma · Brain Tumor
Primary: 16-month Overall Survival (OS) — 64.8 percentage of participants
Phase 3 N=1,097 A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)
Age-related Macular Degeneration
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 — 10.1; 9.2; 8.2; 8.6 Letters
Phase 2 N=50 ET 743 (Yondelis) in Men With Advanced Prostate Cancer
Prostate Cancer
Primary: The Number of Men With Advanced Prostate Cancer Treated With Trabectedin Who Have a PSA Response — 7 participants
Phase 4 N=639 Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
Pulmonary Disease, Chronic Obstructive
Primary: Number of Par. With Chronic Obstructive Pulmonary Disease (COPD) EXs Requiring Hospitalization That Occurred >21 Days Post-discharge/Physician's Office Visit for a COPD…
Phase 4 N=93 Three Intraocular Lenses Designed to Improve Distance, Intermediate and Near Vision Following Lens Extraction
Cataract
Primary: Monocular Mesopic Contrast Sensitivity Without Glare (1.5, 3 Cycles/Degree) — 1.612; 1.582; 1.527; 1.658 log contrast sensitivity units